Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Erlotinib Plus Sirolimus for Patients With Recurrent Malignant Glioma Multiforme

NCT00672243 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT00672243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00672243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Erlotinib Plus Sirolimus for Patients With Recurrent Malignant Glioma Multiforme
Lead sponsor
Duke University
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2007
Completion date
December 31, 2009
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, gliosarcoma